Chinese maker of active pharmaceutical ingredients (APIs), generic formulations and CDMO (contract manufacturing) services.
Chinese maker of active pharmaceutical ingredients (APIs), generic formulations and CDMO (contract manufacturing) services.
Earns from three lines that behave differently: active ingredients sold in bulk to drug makers at prices that follow supply and demand, CDMO fees for developing or making medicines to other companies' specifications under contract, and generic drugs sold at home. Exports to regulated markets rely on its plants passing FDA and European inspections.
In one line: A smaller Chinese Lonza/Cambrex (API/CDMO).
Moat: narrow (scale, regulatory licence). FDA/EU-compliant API manufacturing facilities and scale versus smaller API makers.
Headquarters: Hengdian, Zhejiang, China · Employees: 6,787
Size Apeloa Pharmaceutical (000739.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.37B, the 722nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥19.48 on 18 Nov 2026.
Performance Over six months the shares gained 17.4%, against +3.4% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue fell 15.5% over the last twelve months (peer median +10.3%); the operating margin is 10.1% (peer median 12.7%).
Valuation It trades at 22.9× forward earnings against a peer median of 19.6× (6th most expensive of 14).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 10.9 points above its cost of capital (6.6% WACC).
Next results Next results expected around 5 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥8.85B | CN¥9.76B | CN¥12.0B | CN¥11.4B | CN¥10.5B |
| Revenue growth | — | -19% | +5% | +9% | — |
| Gross profit | CN¥2.91B | CN¥2.37B | CN¥2.68B | CN¥2.73B | CN¥2.34B |
| EBITDA | n/a | CN¥1.56B | CN¥1.61B | CN¥1.64B | CN¥1.30B |
| Net income | CN¥804M | CN¥891M | CN¥1.03B | CN¥1.06B | CN¥989M |
| Free cash flow | CN¥679M | CN¥844M | CN¥768M | CN¥401M | CN¥817M |
| Capital expenditure | CN¥442M | CN¥386M | CN¥461M | CN¥630M | CN¥509M |
| Total debt | CN¥3.00B | CN¥3.41B | CN¥3.01B | CN¥3.43B | CN¥3.70B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Apeloa Pharmaceutical 000739.SZ | $3.37B | +17% | -16% | 10% | 22.9× | 4.7% |
| Zhejiang Huahai Pharmaceutical 600521.SS | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% |
| Porton Pharma Solutions 300363.SZ | $1.66B | +37% | +6% | -2% | n/a | 2.1% |
| Zhejiang NHU 002001.SZ | $11.8B | -22% | +11% | 33% | 9.7× | -8.3% |
| Zhejiang Medicine 600216.SS | $1.51B | -26% | -6% | 7% | 11.5× | -7.8% |
| Zhejiang Xianju Pharmaceutical 002332.SZ | $1.28B | -1% | +8% | 11% | 17.7× | -0.4% |
| Zhejiang Hisun Pharmaceutical 600267.SS | $2.19B | +14% | -7% | 15% | 15.0× | -9.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000739.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.3% | -0.2% | 5th lowest of 21 |
| 6-month return | +17.4% | +3.4% | 8th highest of 20 |
| Distance from 52-week high | -31.6% | -18.6% | 7th lowest of 21 |
| Revenue growth (TTM) | -15.5% | +10.3% | 2nd lowest of 18 |
| Operating margin | 10.1% | 12.7% | 8th lowest of 17 |
| Forward P/E | 22.9× | 19.6× | 6th most expensive of 14 |
| Growth the price implies (Req g, 7 yrs) | 4.7% | -2.8% | 5th most demanding of 11 |
| Growth delivered (Del g) | +4.5% | +6.9% | 4th lowest of 11 |
| Hurdle (Req g minus delivered) | +0.2 pp | -13.3 pp | 4th most demanding of 11 |
| ROIC minus cost of capital | +10.9 pp | +3.7 pp | 4th highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 22.9× | 4.7% | +4.5% |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 150.8× | n/a | n/a |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 13.5× | -3.4% | +10.6% |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | n/a | n/a | n/a |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 19.6× | -2.1% | +12.0% |
| Shanghai Junshi Biosciences 688180.SS | China | $3.48B | -31% | +29% | -15% | n/a | n/a | n/a |
| China National Medicines 600511.SS | China | $3.26B | +3% | +3% | 4% | 10.5× | -10.0% | +5.4% |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 41.0× | 49.2% | +367.3% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 63.6× | n/a | n/a |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 16.8× | n/a | n/a |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | n/a | 58.0% | +4.2% |
| Tasly Pharmaceutical 600535.SS | China | $3.19B | -2% | -4% | 19% | 16.7× | -7.5% | -9.6% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% | +7.8% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% | +5.9% |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.13B | -25% | +136% | 29% | 36.1× | 17.7% | +98.4% |
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $3.12B | -42% | +50% | 3% | 34.2× | n/a | n/a |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 4.0× | -4.1% | -1.0% |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |